CAH
CARDINAL HEALTH INCEvidence as of 2026-09-02Overview · CARDINAL HEALTH INC
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segme…
Management team
- Ms. Michelle D. Greene · Executive VP, Chief Information Officer & Customer Support ServicesFind on LinkedIn
- Ms. Deborah L. Weitzman · Chief Executive Officer of Pharmaceutical & Specialty Solutions SegmentFind on LinkedIn
- Ms. Ola M. Snow · Chief Human Resources OfficerFind on LinkedIn
- Matt Sims · Vice President of Investor RelationsFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.8 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The surviving evidence presents a constructive balance (+0.8 of a possible +2; was +0.8 before debate) with high confidence. Reported revenues grew from $52,277,000,000 in fiscal Q1 2025 (2024-07-01 to 2024-09-30, 3mo) to $64,009,000,000 in fiscal Q1 2026 (2025-07-01 to 2025-09-30, 3mo) and then to $65,627,000,000 in FY 2026 (fiscal quarter ended 2026-07-31). Operating income and gross profit rose over the same comparable periods — operating income from $568,000,000 to $668,000,000 in fiscal Q1 2026 and $707,000,000 in FY 2026, and gross profit from $1,902,000,000 to $2,319,000,000 and $2,397,000,000 respectively. Net income for the listed 3‑month periods increased from $400,000,000 in fiscal Q2 2025 (2024-10-01 to 2024-12-31, 3mo) to $450,000,000 in fiscal Q1 2026 and $467,000,000 in Q2 2026 (2025-10-01 to 2025-12-31, 3mo). Shares outstanding have declined across the sample (from 242,010,503 as of 2024-10-25 to 232,575,728 as of 2026-07-31), with repurchase activity of $375,000,000 in fiscal Q1 2026 consistent with that trend.
The company shows positive operating profitability on a trailing twelve‑month basis — operating income $2,654,000,000 and EBITDA $3,495,000,000 — even as trailing twelve‑month free cash flow is negative $483,000,000 and net cash from operations is negative $123,000,000. Cash and cash equivalents were $4,856,000,000 as of 2026-06-30 against long‑term debt of $2,502,000,000, and reported trailing EPS is $6.15 while free cash flow per share is negative $2.038. Multiple institutional filings in late August and early September 2026 show new or increased positions, and CAH is a 0.09 percent weight in IVV as of 2026-09-02T13:45:47.228469+00:00.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported revenues increased from $52,277,000,000 in fiscal Q1 2025 (2024-07-01 to 2024-09-30, 3mo) to $64,009,000,000 in fiscal Q1 2026 (2025-07-01 to 2025-09-30, 3mo) and then to $65,627,000,000 in fiscal Q2 2026 (2025-10-01 to 2025-12-31, 3mo).
XBRL companyfacts · 0000721371-24-000121Operating income rose across comparable periods: $568,000,000 in fiscal Q1 2025 (2024-07-01 to 2024-09-30, 3mo), $568,000,000 (same source) to $668,000,000 in fiscal Q1 2026 (2025-07-01 to 2025-09-30, 3mo) and $707,000,000 in fiscal Q2 2026 (2025-10-01 to 2025-12-31, 3mo).
XBRL companyfacts · 0000721371-25-000130Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, CARDINAL HEALTH INC (CAH) is a constituent of the iShares Core S&P 500 ETF (IVV).
ETF constituents · market dataThe reported weight of CAH in IVV is 0.09 percent of the fund as of 2026-09-02T13:45:47.228469+00:00.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Lone Peak Global Investors LLC increased its stake in Cardinal Health by 6.1% in the second quarter, holding 121,090 shares as reported on 2 September 2026.
News · thelincolnianonline.com · 2026-09-02Van ECK Associates Corp boosted its position in Cardinal Health by 9.4% in the second quarter and held 33,353 shares after the purchases, as reported on 2 September 2026.
News · thelincolnianonline.com · 2026-09-02Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Free cash flow for the trailing twelve months is negative $483,000,000.
Valuation inputs · SEC XBRL + stored EOD closeNet cash provided by (used in) operating activities for the trailing twelve months is negative $123,000,000.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The company’s recent quarterly figures show a clear pattern of improving core performance: sequential and year-over-year revenue growth, expanding gross profit, rising operating income and incremental net income across the reported quarters. Shares outstanding have been trending down with documented repurchase activity, which amplifies per-share earnings and aligns with the rise in reported EPS; operating profitability measures (TTM operating income and EBITDA) are positive and cash on the balance sheet exceeds reported long-term debt on the provided dates. Institutional filings and multiple buy-side analyst initiatives in the provided context further support a favorable market read. The strongest negative datapoints (negative trailing free cash flow, negative net operating cash on a TTM basis, and reported negative stockholders’ equity) are factual but come with mixed context: operating cash conversion appears to have lagged despite accounting profitability, and reported equity balances reflect historical adjustments — these caveats reduce the strength of the negative case relative to the improving income statement and share-reduction evidence.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.30
20 surviving claims rest on 12 distinct sources; the heaviest analyst carries 35% of them, and 100% of what the desk raised survived the debate.
The evidence set rests on a moderate number of distinct sources, many of them primary (SEC filings), which supports factual grounding for the accounting and share-count claims. However, one analyst produced a disproportionate share of the surviving claims and the desk reported no losses during debate, which raises fragility from potential analyst-concentration and confirmation effects — treat the read as informational but relatively dependent on a few contributors.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
14 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+1.1 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.5 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on CAH Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.